OSE Immuno

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

03 Apr 2025 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

26 Mar 2025 13:20:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

11 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

06 Mar 2025 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

24 Feb 2025 01:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

20 Feb 2025 12:05:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

29 Jan 2025 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

28 Jan 2025 01:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

13 Jan 2025 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

11 Dec 2024 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

02 Dec 2024 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

04 Nov 2024 01:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

17 Oct 2024 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

26 Sep 2024 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

10 Sep 2024 01:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

24 Jul 2024 02:55:00 By Nasdaq GlobeNewswire

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

03 Jul 2024 12:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

01 Jul 2024 01:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

24 Jun 2024 01:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

20 Jun 2024 01:30:00 By Nasdaq GlobeNewswire